Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Pro Medicus Limited (ASX:PME): Cloud Imaging Expansion Across North America

Pro Medicus Limited (ASX:PME) is a healthcare informatics company providing medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide. Its Visage 7 platform remains central to the company’s 2026 expansion across large health systems, particularly in North America, where cloud-based …

Aditi Sarkar | 05 October 2026

Medibank Private Limited (ASX:MPL): Preventative Health and Virtual Care Shape Its 2026 Strategy

Medibank Private Limited (ASX:MPL) is an Australian health company that provides private health insurance and health-related services through brands including Medibank and ahm. In 2026, the group is continuing to develop preventative health, virtual care and alternative clinical pathways as part of a broader …

Aditi Sarkar | 05 October 2026

Ramsay Health Care Limited (ASX:RHC): Reshaping Hospital Operations Across Australia and Europe

Ramsay Health Care Limited (ASX:RHC) operates private hospitals and healthcare services across Australia and selected international markets. In 2026, the group’s focus is on reshaping parts of its European operations while improving capacity utilisation, clinical productivity and service delivery across its Australian hospital network.

Aditi Sarkar | 05 October 2026

Sonic Healthcare Limited (ASX:SHL): European Laboratory Integration Shapes FY2026 Operations

Sonic Healthcare Limited (ASX:SHL) is one of the world’s largest medical diagnostics companies, providing laboratory medicine and diagnostic imaging services to medical practitioners, hospitals, community health services and patients. During FY2026, the group’s operating agenda centred on integrating acquired laboratory networks, capturing efficiencies in …

Aditi Sarkar | 05 October 2026

CSL (ASX:CSL) Expands Rare Disease Pipeline With Lixudebart Agreement

CSL Limited (ASX:CSL) is a global biotechnology company with operations spanning therapies for serious and rare diseases. CSL shares were quoted at A$176.92 on 5 October 2026. Its latest announcement adds lixudebart to the company’s development pipeline through an exclusive co-development and co-promotion agreement …

Sonal Goyal | 05 October 2026

Dimerix (ASX:DXB) Marks Four-Year DMX-200 Patient Milestone as ACTION3 Phase 3 Continues

Dimerix Limited (ASX:DXB) is a clinical-stage biopharmaceutical company developing therapies for kidney diseases with significant unmet medical need. DXB shares were quoted at A$0.24 on 5 October 2026. Its lead program, DMX-200, is in Phase 3 development for focal segmental glomerulosclerosis, or FSGS, while …

Sonal Goyal | 05 October 2026

CSL Limited (ASX:CSL): Plasma Efficiency and Manufacturing Focus in 2026

CSL Limited (ASX:CSL) is a global biotechnology company developing and delivering medicines for serious and complex diseases, including plasma-derived therapies, vaccines, and treatments in iron deficiency and nephrology. In 2026, a key operational theme is how the group is improving plasma collection and manufacturing …

Aditi Sarkar | 05 October 2026

Dimerix (ASX:DXB) Reaches Four-Year DMX-200 Patient Milestone as ACTION3 Follow-Up Deepens

Dimerix Limited (ASX:DXB) has recorded a long-duration milestone in its DMX-200 program, with the first patient completing two years in the ACTION3 Phase 3 study followed by another two years in its open-label extension. The four-year participation period adds a new layer of long-term …

Aditi Sarkar | 05 October 2026

Medibank Private Ltd (ASX:MPL) Shares Rise 1.33% – What’s Behind Today’s Move?

On 2 October 2026, Medibank shares were trading at $4.57, up 1.33% for the session. The company's 2026 full-year results, released in August, reported growth in underlying profit, policyholders and health services, along with a higher ordinary dividend.

Sonal Goyal | 04 October 2026

Ramsay Health Care Ltd (ASX:RHC) Shares Slip 1.03% – Here’s What Investors Need to Know

On 2 October 2026, Ramsay shares were trading at $53.92, down 1.03% for the session. The company's full-year results, released in August, reported higher underlyingEarningsacross all regions, a higherDividendand progress toward the proposed separation of Ramsay Santé.

Sonal Goyal | 04 October 2026
Support

Hi! How can we help you today?

Loading…